A Phase I/II Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Conditions

Lung

What is the purpose of this trial?

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Astex Pharmaceuticals, Inc.
Dates:
04/25/2014
Last Updated:
Study HIC#:
1307012392